Overview

Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation

Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
This study is designed to determine the safety of RSD1235 in patients with atrial fibrillation.
Phase:
Phase 3
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborators:
Cardiome Pharma
Correvio International Sarl